Early Access — free while we kick the tires
EdgarHawk

EBS Emergent BioSolutions Inc. Insider Trading

1 filing analyzed · Latest 2025-05-15
Insider buys
1
Insider sells
0
Unique insiders
1
Direction
Net buying

Historically, medium-priority insider buys have outperformed the S&P 500 by a median ~1% over the 30 days after filing — the edge is concentrated in that first month (n ≈ 7,520, 2022-2026). Past results don't predict the future. How we measure this ↗

May 2025
2025-05-15
medium
President and CEO
60,000 shares
$349,800
@ $5.83
Significance 4/10

CEO Papa Joseph C buys 60,000 shares at $5.83, increasing stake 21.2% to 342.5K shares amid stock down 62.8% from 52-week high.

Papa Joseph C, President and CEO, purchased 60,000 shares at $5.83 on 2025-05-13 for $349,800.00, increasing his holdings from 282.5K to 342.5K shares. The purchase occurs with the stock trading at $5.49 currently, down 62.8% from its 52-week high of $14.77, though up 18.6% over the past 30 days. The company reported latest quarterly revenue of $222.2M and net income of $68.0M, but was unprofitable over its most recent full fiscal year and has declined 0.5% year-over-year in revenue. The timing of this buy—into a depressed valuation but at a 62.8% discount from peak—warrants examination of whether the transaction reflects genuine assessment of business stabilization or reflects other factors. Investors should monitor whether this purchase precedes any material announcements regarding operational recovery.

More Chemicals and Allied Products companies

Get alerts for EBS

Add EBS to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access